20856855

Source:http://linkedlifedata.com/resource/pubmed/id/20856855

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001038, umls-concept:C0015272, umls-concept:C0017337, umls-concept:C0205314, umls-concept:C0332453, umls-concept:C0441655, umls-concept:C0679622, umls-concept:C0684249, umls-concept:C1326205, umls-concept:C1512474, umls-concept:C1622186
pubmed:issue	9
pubmed:dateCreated	2010-9-21
pubmed:abstractText	Lung cancer is the leading cause of cancer mortality worldwide, yet the therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective. In addition, validated histone deacetylase (HDAC) inhibitors for the treatment of solid tumors remain to be developed. Here, we propose a novel HDAC inhibitor, OSU-HDAC-44, as a chemotherapeutic drug for NSCLC.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101285081
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Actins, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzamides, http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxamic Acids
pubmed:status	MEDLINE
pubmed:issn	1932-6203
pubmed:author	pubmed-author:ChangJer-WeiJW, pubmed-author:ChenChien-TienCT, pubmed-author:ChenChing-ShihCS, pubmed-author:SalunkeSantoshS, pubmed-author:TanYi-Hung CarolYH, pubmed-author:TangYen-AnYA, pubmed-author:WangYi-ChingYC, pubmed-author:WeiTzi-TangTT, pubmed-author:WenWei-LingWL
pubmed:issnType	Electronic
pubmed:volume	5
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	e12417
pubmed:meshHeading	pubmed-meshheading:20856855-Acetylation, pubmed-meshheading:20856855-Actins, pubmed-meshheading:20856855-Animals, pubmed-meshheading:20856855-Antineoplastic Agents, pubmed-meshheading:20856855-Apoptosis, pubmed-meshheading:20856855-Benzamides, pubmed-meshheading:20856855-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:20856855-Cell Line, Tumor, pubmed-meshheading:20856855-Cell Proliferation, pubmed-meshheading:20856855-Disease Models, Animal, pubmed-meshheading:20856855-Female, pubmed-meshheading:20856855-Gene Expression Regulation, Neoplastic, pubmed-meshheading:20856855-Histone Deacetylase Inhibitors, pubmed-meshheading:20856855-Humans, pubmed-meshheading:20856855-Hydroxamic Acids, pubmed-meshheading:20856855-Lung Neoplasms, pubmed-meshheading:20856855-Mice, pubmed-meshheading:20856855-Mice, Inbred BALB C, pubmed-meshheading:20856855-Mice, Nude, pubmed-meshheading:20856855-Xenograft Model Antitumor Assays
pubmed:year	2010
pubmed:articleTitle	A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
pubmed:affiliation	Institute of Basic Medical Science, National Cheng Kung University, Tainan, Taiwan, Republic of China.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't